Indrayani Biotech Ltd

Indrayani Biotech Limited announced the appointment of Mr. C.S. Shanmuga Sundar as Company Secretary & Compliance Officer, effective September 9, 2026, succeeding Ms. Ramya Ravi who resigned on June 3, 2026, according to a filing with the BSE Limited. Mr. Shanmuga Sundar, a qualified Company Secretary, previously held the position of Company Secretary at Peiner Smag Machinery and brings experience in corporate secretarial functions, statutory compliance, and corporate governance.

Indrayani Biotech Ltd share price tumbled by 8.91% to Rs 7.16. The Company's net profit saw a strong growth of 808.33% to Rs 1.09 crore, while revenue from operations gained significantly 107.88% to Rs 72.78 crore in Q1FY26 over Q4FY25. The market capitalization of Other Agricultural Products industry group stocks on BSE stood at Rs 57073.02 crore, gaining 6.64%. It has improved by 0.99% over last one week and gained upto 1.62% in last one month while the market capitalization of Indrayani Biotech Ltd has slipped by 9.25% and 31.03% in the same period respectively. Profit before tax (PBT) of Indrayani Biotech Ltd stood at Rs 0.97 crore in Q1 FY26, crashing by 88.34% year-on-year, and tumbling by 792.86% quarter-on-quarter. EBITDA came in at Rs 3 crore, plunging by 138.62% YoY and surging by 67.86% sequentially. Total expenses witnessed a sharp rise of 110.35% to Rs 69.92 crore in Q1FY26 over Q1FY25. During the quarter, cost of materials consumed stood at Rs 51.38 crore, jumping 96.86% YoY, while employee benefits expense was at Rs 7.49 crore, witnessing a strong rise of 134.06% YoY. For the TTM ended FY26, revenue from operations plunged by 21.66% to Rs 130.23 crore, while net profit witnessed a sharp fall of 158.64% to Rs 6.11 crore, compared to previous TTM. EBITDA surged by 2080% to Rs 3.13 crore, and PBT tanked by 152.32% to Rs 5.74 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 6.74 crore in FY26, as against Rs 30.35 crore in FY25. Indrayani Biotech Ltd crashed 50.24% in last one year, underperforming the benchmark BSE Sensex which has softened by 4.36% during the same period.

Indrayani Biotech Ltd share price crashed 8.91% to Rs 7.16. The Company's net profit surged by 808.33% to Rs 1.09 crore, while revenue from operations gained significantly 107.88% to Rs 72.78 crore in Q1FY26 over Q4FY25. The market capitalization of Other Agricultural Products industry group stocks on BSE stood at Rs 57130.8 crore, rising 6.64%. It has improved by 0.77% over last one week and gained upto 1.52% in last one month while the market capitalization of Indrayani Biotech Ltd has nosedived by 16.56% and 33.03% in the same period respectively. Profit before tax (PBT) of Indrayani Biotech Ltd stood at Rs 0.97 crore in Q1 FY26, tanking 88.34% year-on-year, and nosediving by 792.86% quarter-on-quarter. EBITDA came in at Rs 3 crore, plunging by 138.62% YoY and rallying 67.86% sequentially. Total expenses soared by 110.35% to Rs 69.92 crore in Q1FY26 over Q1FY25. During the quarter, cost of materials consumed stood at Rs 51.38 crore, surging by 96.86% YoY, while employee benefits expense was at Rs 7.49 crore, jumping 134.06% YoY. For the TTM ended FY26, revenue from operations plunged by 21.66% to Rs 130.23 crore, while net profit witnessed a sharp fall of 158.64% to Rs 6.11 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 2080% to Rs 3.13 crore, and PBT tanked by 152.32% to Rs 5.74 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 6.74 crore in FY26, as against Rs 30.35 crore in FY25. Indrayani Biotech Ltd tumbled by 45.79% in last one year, underperforming the benchmark BSE Sensex which has slipped by 3.21% during the same period.

Indrayani Biotech Limited will hold a board meeting on Monday, August 17, 2026, to approve the audited financial statements for the quarter and financial year ended March 31, 2026, and to consider the auditors' report for the same period. The board will also approve the audited financial results to be disseminated to the stock exchange and authorize the text of an advertisement for publication.

Indrayani Biotech will hold a meeting of the Board of Directors of the Company on 9 April 2026.

Net profit of Indrayani Biotech declined 75.00% to Rs 0.06 crore in the quarter ended December 2025 as against Rs 0.24 crore during the previous quarter ended December 2024. Sales rose 102.14% to Rs 35.01 crore in the quarter ended December 2025 as against Rs 17.32 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales35.0117.32 102 OPM %7.9716.86 - PBDT1.151.89 -39 PBT0.140.43 -67 NP0.060.24 -75 Powered by Capital Market - Live

Indrayani Biotech will hold a meeting of the Board of Directors of the Company on 26 February 2026.Powered by Capital Market - Live

Net profit of Indrayani Biotech declined 25.41% to Rs 0.91 crore in the quarter ended September 2025 as against Rs 1.22 crore during the previous quarter ended September 2024. Sales rose 16.68% to Rs 35.95 crore in the quarter ended September 2025 as against Rs 30.81 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales35.9530.81 17 OPM %6.8216.59 - PBDT2.363.99 -41 PBT1.061.20 -12 NP0.911.22 -25 Powered by Capital Market - Live

Indrayani Biotech will hold a meeting of the Board of Directors of the Company on 11 December 2025.Powered by Capital Market - Live

Indrayani Biotech has postponed the meeting of the Board of Directors which was scheduled to be held on 14 November 2025. The meeting will now be held on to a later date.Powered by Capital Market - Live